NCT04432454 - Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 29, 2020

Primary Completion Date

January 28, 2025

Study Completion Date

January 28, 2025

Conditions

Metastatic Breast Cancer

Interventions

DRUG

Lasofoxifene and abemaciclib (VERZENIO (R)).

Lasofoxifene 5 mg given once a day orally and abemaciclib 150 mg given twice a day orally.

Trial Locations (16)

22408

Hematology Oncology Associates of Fredericksburg, Fredericksburg

32224

Mayo Jacksonville, Jacksonville

43210

The Ohio State University Comprehensive Cancer Center, Columbus

44195

Cleveland Clinic, Cleveland

46601

Beacon Health System Memorial Regional Cancer Center, South Bend

55905

Mayo Clinic Rochester, Rochester

61704

Illinois Cancer Care, Peoria

75230

Mary Crowley Cancer Research, Dallas

77030

Oncology Consultants, P.A., Houston

85364

Yuma Regional Medical Center, Yuma

92708

Compassionate Cancer Care Med Group - Clinic Aid USA - Fountain Valley, Fountain Valley

95403

St. Joseph Health, Santa Rosa

98405

Northwest Medical Specialists, PLLC (NWMS), Tacoma

35294-3300

University of Alabama at Birmingham (UAB) - Comprehensive Cancer Center, Birmingham

07109

New Jersey Cancer Care, PA, Belleville

77030-4009

MD Anderson Cancer Center, Houston

All Listed Sponsors

lead

Sermonix Pharmaceuticals Inc.

INDUSTRY